Sphera Funds Management Ltd. Relmada Therapeutics, Inc. Transaction History

Sphera Funds Management Ltd.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$18.3 - $37.02 $5.01 Million - $10.1 Million	-273,600 Reduced 58.61%	193,230 $7.15 Million
Q2 2022 Aug 15, 2022	BUY	$16.5 - $30.34 $2.9 Million - $5.33 Million	175,578 Added 60.28%	466,830 $8.87 Million
Q1 2022 May 16, 2022	SELL	$16.72 - $26.99 $3.13 Million - $5.05 Million	-186,956 Reduced 39.1%	291,252 $7.86 Million
Q4 2021 Feb 14, 2022	BUY	$16.93 - $26.82 $8.1 Million - $12.8 Million	478,208 New	478,208 $10.8 Million

12.3M

229K

138K

Ticker RLMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,608,500
Market Cap $10.9M
Description
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...

Get notified when there are updates to the investment portfolio of Sphera Funds Management Ltd., based on Form 13F filings with the SEC.

Stay updated on Sphera Funds Management Ltd. with notifications on news.